Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma

被引：9
|
作者：
Ansell, Stephen M. [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA
来源：
LANCET HAEMATOLOGY | 2019年 / 6卷 / 01期
关键词：
CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; PHASE-II; NIVOLUMAB; PEMBROLIZUMAB; MULTICOHORT; BLOCKADE; FAILURE;
D O I：
10.1016/S2352-3026(18)30210-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E2 / E3
页数：2
相关论文
共 50 条
  • [31] Real-world retrospective analysis of immune checkpoint inhibitor therapy for relapsed or refractory Hodgkin's lymphoma
    Oyake, Tatsuo
    Maeta, Takahiro
    Takahata, Takenori
    Tamai, Yoshiko
    Kameoka, Yoshihiro
    Takahashi, Naoto
    Miyairi, Yasuro
    Murai, Kazunori
    Shimosegawa, Kenji
    Yoshida, Kozue
    Inokura, Kyoko
    Fukuhara, Noriko
    Harigae, Hideo
    Sato, Ryo
    Ishizawa, Kenichi
    Tajima, Katsushi
    Saitou, Souichi
    Fukatsu, Masahiko
    Ikezoe, Takayuki
    Tsunoda, Saburo
    Mita, Masayuki
    Mori, Jinichi
    Kowata, Shugo
    Ito, Shigeki
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2024, 64 (03) : 191 - 202
  • [32] Patterns of Progression on Immune Checkpoint Inhibitor Therapy for Relapsed Hodgkin Lymphoma: Implications for the Potential Role of Radiation Therapy
    Burlile, J. F.
    Breen, W.
    Hwang, S. R.
    Higgins, A. S.
    Nedved, A. N.
    Harmsen, W. S.
    Witzig, T.
    Micallef, I. N.
    Hoppe, B. S.
    Habermann, T. M.
    Thanarajasingam, G.
    Johnston, P.
    Inwards, D. J.
    Bennani, N.
    Peterson, J. L.
    Stish, B. J.
    Rule, W. G.
    Ansell, S. M.
    Lester, S. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S54 - S55
  • [33] Tumour Microenvironment Contribution to Checkpoint Inhibitor Therapy in Classic Hodgkin Lymphoma
    Gloghini, Annunziata
    Carbone, Antonino
    HEMATO, 2024, 5 (02): : 199 - 207
  • [34] Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma
    Liu, W. Robert
    Shipp, Margaret A.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2017, : 310 - 316
  • [35] Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma
    Liu, W. Robert
    Shipp, Margaret A.
    BLOOD, 2017, 130 (21) : 2265 - 2270
  • [36] Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices
    Gajra, Ajeet
    Klink, Andrew J.
    Nabhan, Chadi
    Feinberg, Bruce
    BLOOD, 2019, 134
  • [37] Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma
    Merryman, Reid W.
    Carreau, Nicole A.
    Advani, Ranjana H.
    Spinner, Michael A.
    Herrera, Alex F.
    Chen, Robert
    Tomassetti, Sarah
    Ramchandren, Radhakrishnan
    Hamid, Muhammad
    Assouline, Sarit
    Santiago, Raoul
    Wagner-Johnston, Nina
    Paul, Suman
    Svoboda, Jakub
    Bair, Steven M.
    Barta, Stefan K.
    Liu, Yang
    Nathan, Sunita
    Karmali, Reem
    Burkart, Madelyn
    Torka, Pallawi
    David, Kevin A.
    Wei, Catherine
    Lansigan, Frederick
    Emery, Lukas
    Persky, Daniel
    Smith, Sonali M.
    Godfrey, James
    Chavez, Julio
    Cohen, Jonathan B.
    Troxel, Andrea B.
    Diefenbach, Catherine
    Armand, Philippe
    ONCOLOGIST, 2020, 25 (06): : E993 - E997
  • [38] Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
    Veldman, Johanna
    Visser, Lydia
    van den Berg, Anke
    Diepstra, Arjan
    CANCER TREATMENT REVIEWS, 2020, 82
  • [39] Classical Hodgkin lymphoma
    Brice, Pauline
    de Kerviler, Eric
    Friedberg, Jonathan W.
    LANCET, 2021, 398 (10310): : 1518 - 1527
  • [40] Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway
    Xiao-Yin Zhang
    Graham P. Collins
    Current Oncology Reports, 2022, 24 : 1477 - 1488
12345